Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer. Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy. Now, researchers… Read More
Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC). CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer… Read More
This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More
For Rare Disease Day 2024, Diana Spencer provides a round-up of the latest breakthroughs in the treatment of rare disease. Study reveals therapeutic potential of mRNA in rare diseases Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare… Read More
The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study… Read More
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick, about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. At the beginning of 2023, proteomics company Nautilus Biotechnology… Read More
This paid-for advertorial by IRBM appeared in DDW Volume 24 – Issue 2, Spring 2023 The landscape for treating rare cancers is changing with advances in molecular genetics, novel drug modalities and patient-derived models. Dr Alessandro Carugo, IRBM, explains how building unique drug discovery strategies and expert alliances is reshaping the… Read More
Rare diseases are often overlooked for funding and research, but with various incentives and priority review programmes now in place, many companies are beginning to explore these unusual but often devastating conditions. This Rare Disease Day we provide an overview of the progress that has been made in… Read More
Cancer Research UK, The University of Manchester and Roche have opened a multi-drug, precision medicine trial for people with rare cancers. The trial is set up to recruit both paediatric and adult patients with any rare cancer type and is one of very few precision medicine platform… Read More
